AstraZeneca firing should also be halted for those over 60 – EMA official – –

AstraZeneca firing should also be halted for those over 60 – EMA official – –

Syringes with vaccines against AstraZeneca coronavirus disease (COVID-19) are being prepared in Fasano, Italy, April 13, 2021. REUTERS / Alessandro Garofalo

Countries should also avoid giving the Astrazeneca coronavirus vaccine to people over 60, the head of the EU medicines regulator’s COVID-19 task force said on Sunday, amid fears over blood clotting rare and as more vaccines become available.

The European Medicines Agency (EMA) considers the Astrazeneca vaccine to be safe for all age groups. However, several Member States of the European Union have stopped giving it to people below a certain age, usually between 50 and 65 years old, limiting its use to the older population, due to the rare cases of coagulation. blood, mainly in young people.

“In the context of a pandemic, our position was and is that the risk-benefit ratio remains favorable for all age groups,” COVID-19 task force leader Marco Cavaleri told Italian newspaper La Stampa.

However, as the number of COVID-19 cases decreases and given that the younger population is less at risk from COVID-19, Cavaleri said it would be better to use COVID-vaccines on them. 19 based on messenger RNA (mRNA), such as Moderna and the Pfizer-BioNTech vaccines.

When asked if health authorities should avoid giving the Astrazeneca vaccine to people over the age of 60, Cavaleri replied: “Yes, and many countries, like France and Germany, are considering it. in light of greater availability of mRNA vaccines. “

The Italian government said on Friday it would limit the use of the AstraZeneca vaccine to people over the age of 60, after a teenager who received the vaccine died from a rare form of blood clotting. Read more

Like many European countries, Italy briefly halted AstraZeneca inoculations in March due to concerns about rare problems with blood clotting.

It took them up the following month with the recommendation that the product be ‘preferably’ used for people over 60, after the EMA said its benefits outweighed the risks.

Our Standards: Thomson Reuters Trust Principles.


Please enter your comment!
Please enter your name here